Inhibition of Stimulated Interleukin-2 Production in Whole Blood: A Practical Measure of Cyclosporine Effect
Reads0
Chats0
TLDR
In the search for a pharmacodynamic marker to better guide immunosuppressive therapy, the relationship between this simple, biologically relevant measure of CSA effect and clinical outcome should be determined.Abstract:
Background: Prediction of cyclosporine (CSA) efficacy and toxicity in individual patients is difficult. There is no practical, biologically relevant, pharmacodynamic measure of CSA effect. A major effect of CSA is to decrease interleukin-2 (IL-2) production; however, measurement of this effect in isolated lymphocytes as a marker of response to CSA has been problematic.
Methods: CSA inhibition of phytohemagglutinin-P (PHA)-stimulated IL-2 production, measured by ELISA, was studied ex vivo in whole blood drawn before, and after subjects received 4 mg/kg oral CSA.
Results: Four hours after CSA was administered, the mean (± SD) CSA concentration was 702 ± 196 μg/L and PHA-stimulated IL-2 production decreased by 68.7% ± 17.2% ( P <0.0001; n = 17). Twenty-four hours after CSA was administered, concentrations were low (64 ± 24 μg/L), with no inhibition of IL-2 production. A rapid, concentration-dependent response occurred. Maximum CSA concentrations (944 ± 187 μg/L) and maximum inhibition of IL-2 production (86.9% ± 13.7%) occurred 90 min after subjects received CSA. In vitro, 32.5–1200 μg/L CSA also inhibited PHA-stimulated IL-2 production in whole blood in a dose-dependent fashion with a similar IC50 (∼300–400 μg/L) ex vivo and in vitro.
Conclusion: In the search for a pharmacodynamic marker to better guide immunosuppressive therapy, the relationship between this simple, biologically relevant measure of CSA effect and clinical outcome should be determined.read more
Citations
More filters
Journal ArticleDOI
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy : Second Consensus Report
Mercè Brunet,Teun van Gelder,Anders Åsberg,Vincent Haufroid,Vincent Haufroid,Dennis A. Hesselink,Loralie J. Langman,Florian Lemaitre,Pierre Marquet,Christoph Seger,Maria Shipkova,Alexander A. Vinks,Alexander A. Vinks,Pierre Wallemacq,Eberhard Wieland,Jean-Baptiste Woillard,Markus J. Barten,Klemens Budde,Helena Colom,Maja Theresa Dieterlen,Laure Elens,Kamisha L. Johnson-Davis,Paweł K. Kunicki,Iain MacPhee,Satohiro Masuda,Binu S. Mathew,Olga Millán,Tomoyuki Mizuno,Tomoyuki Mizuno,Dirk Jan A.R. Moes,Caroline Monchaud,Ofelia Noceti,Tomasz Pawinski,Nicolas Picard,Ron H.N. van Schaik,Claudia Sommerer,Nils Tore Vethe,Brenda C. M. de Winter,Uwe Christians,Stein Bergan +39 more
TL;DR: It is concluded that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade, and the Expert Committee concludes that Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized PK approaches with PG, and valid biomarkers to further personalize tacolimus therapy and to improve long-term outcomes for treated patients.
Journal ArticleDOI
Therapeutic Monitoring of Calcineurin Inhibitors for the Nephrologist
TL;DR: The purpose of this article is to review the current understanding of CNI pharmacokinetics and its relevance to proper dosing and monitoring of these medications and discusses the effect of adjunctive immunosuppressive agents on CNI Pharmacokinetic and dosing.
Journal ArticleDOI
Patient management by neoral C2 monitoring: An international consensus statement
TL;DR: The Consensus on Neoral C2: Expert Review in Transplantation (CONCERT) attendees achieved consensus on the following points, based on currently available data from independent clinical studies using Neoral (cyclosporine microemulsion): higher C2 levels are highly correlated with a lower risk of acute rejection during the early posttransplant period in patients receiving Neoral.
Journal ArticleDOI
New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation
TL;DR: New insights for the calcineurin inhibitors (CNIs) cyclosporine and tacrolimus and the antimetabolite mycophenolic acid (MPA) are highlighted and the possible consequences are discussed.
Journal ArticleDOI
New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine.
TL;DR: Initial investigations suggest that monitoring a 2-h postdose concentration C(2) may provide a more efficacious alternative to trough monitoring for optimizing therapy with Neoral and both pharmacokinetic and pharmacodynamic considerations support the concept that determination of cyclosporine during the absorption phase (0-4 h) might offer a better prediction of cyclOSporine immunosuppressive efficacy.
References
More filters
Journal ArticleDOI
The mechanism of action of cyclosporin A and FK506.
Steffan N. Ho,Neil A. Clipstone,Luika Timmermann,Jeffrey P. Northrop,Isabella A. Graef,David Fiorentino,Jamie Nourse,Gerald R. Crabtree +7 more
TL;DR: The immunosuppressants cyclosporin A (CsA), FK506, and rapamycin suppress the immune response by inhibiting evolutionary conserved signal transduction pathways by creating composite surfaces that block the activity of specific targets.
Journal ArticleDOI
FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin.
Stephen J. O'Keefe,Jun'ichi Tamura,Jun'ichi Tamura,Randall L. Kincaid,Michael J. Tocci,Edward A. O'Neill +5 more
TL;DR: It is reported that transfection of a calcineurin catalytic subunit increases the 50% inhibitory concentration of the immunosuppressants FK-506 and CsA, and that a mutant subunit acts in synergy with phorbol ester alone to activate the interleukin-2 promoter in a drug-sensitive manner.
Journal ArticleDOI
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
Flavio Vincenti,Robert L. Kirkman,Susan Light,Ginny L. Bumgardner,Mark D. Pescovitz,Philip F. Halloran,J. Neylan,Alan H. Wilkinson,Henrik Ekberg,Robert S. Gaston,Lars Bäckman,James F. Burdick +11 more
TL;DR: Daclizumab is a genetically engineered human IgG1 monoclonal antibody that binds specifically to the α chain of the interleukin-2 receptor and may thus reduce the risk of rejection after renal transplantation.
Journal ArticleDOI
Clinical Pharmacokinetics of Cyclosporin
TL;DR: Therapeutic drug monitoring of cyclosporin is essential for several reasons, including minimising drug toxicity by maintaining trough concentrations below that which toxicity is most likely to occur, and monitoring for compliance since patient non-compliance with drug regimens is a significant reason for graft loss after 60 days.
Journal ArticleDOI
Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
Anders Lindholm,Barry D. Kahan +1 more
TL;DR: This association suggests that improved cyclosporine pharmacokinetic monitoring may aid in improving outcome after kidney transplantation, and an equation is described to provide initial oral dose prediction.